Orchid Pharma Board Approves Q3 FY26 Unaudited Financial Results
Orchid Pharma reported Q3 FY26 unaudited results with standalone and consolidated net sales of ₹20,726.70 lakhs. The company recognized ₹711.27 lakhs in exceptional items due to new labor codes. QIP proceeds of ₹39,180 lakhs are being utilized, with ₹6,198 lakhs remaining. Amalgamation with Dhanuka Laboratories is progressing, with the next NCLT hearing on March 2, 2026.
The announcement includes the financial results for the quarter and year-to-date, which are material information for investors. Additionally, the update on the amalgamation process and QIP fund utilization are significant corporate actions that can impact the company's future. The qualified conclusion from auditors introduces some uncertainty.
The announcement reports financial results and ongoing corporate actions. While the results show a mixed performance compared to previous periods, and there are ongoing legal processes for amalgamation, there are no overwhelmingly positive or negative indicators in the provided text. The qualified conclusion from the auditors also tempers a positive sentiment.
Orchid Pharma Limited announced that its Board of Directors, in a meeting held on February 11, 2026, approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The auditors, M/s. Singhi & Co., have issued their limited review reports on these results.
The company reported standalone net sales of ₹20,726.70 lakhs for the quarter ended December 31, 2025, and ₹57,372.00 lakhs for the nine months ended December 31, 2025. Consolidated net sales for the same periods were ₹20,726.70 lakhs and ₹57,372.00 lakhs respectively.
Notable items include an incremental liability of ₹711.27 lakhs on account of past service cost due to the New Labour Codes, recognized under exceptional items. The company also provided an update on the utilization of proceeds from its Qualified Institutional Placement (QIP) of ₹39,180 lakhs (net), raised on June 27, 2023. As of December 31, 2025, the entire net proceeds have been received, with ₹33,256 lakhs utilized and ₹6,198 lakhs remaining, primarily for general corporate purposes and investment in subsidiary OBPL.
Furthermore, the company is proceeding with the amalgamation of its holding company, Dhanuka Laboratories Limited. The scheme has received no-objection letters from BSE and NSE. The next hearing for the Joint Company Petition is scheduled for March 02, 2026, at the Hon'ble NCLT.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.